BioSpace News Archive

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), today announced financial results for the full year ended December 31, 2021 and recent corporate highlights.

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced financial results for the fourth quarter and full-year ended December 31, 2021 and provided a business update.

Evofem Biosciences, Inc., (Nasdaq: EVFM) today presented data at the Academy of Managed Care Pharmacy (AMCP) annual meeting showing EVO100 (the investigational name for Phexxi®) provided a significant decrease in gonorrhea and chlamydia infections in women as well as additional patient health outcomes related to satisfaction with use of the investigational product.

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their upcoming webinar, “De-risking Bispecifics Early-on: How tight is too tight? How weak is too weak?” will occur on Wednesday, April 6, 2022 at 2p.m. ET/ 11A.M. PT.

The global controlled substance market was valued at ~US$ 64 Bn in 2018, and is projected to reach a value of US$ 115 Bn by 2027, expanding at a CAGR of 7% during the forecast period of 2021 to 2027.

According to the report, the global hospital acquired infection treatment (HAI) market was valued at US$ 31.0 Bn in 2018 and is anticipated to expand at a CAGR of 2.5% from 2019 to 2027.

According to the report, the global Ophthalmic Drugs Market was valued at US$ 26.0 Bn in 2018 and is anticipated to expand at a CAGR of 4.1% from 2019 to 2030.

According to the report, the global organ preservation solution market was valued at US$ 193.4 Mn in 2018 and is projected to expand at a CAGR of 10.5% from 2019 to 2030.

The global organ transplant rejection medications market is expected to reach a value of ~US$ 6.3 Bn by the end of the forecast period.

According to the report, the global scar treatment market was valued at US$ 15.08 Bn in 2018 and is projected to expand at a CAGR of 8.3% from 2019 to 2030.